Tumor-induced lymphangiogenesis in cervical lymph nodes in oral melanoma-bearing mice

Journal of Experimental and Clinical Cancer Research

Volumn 31, Issue 1, 2012, Pages

  Ozasa, Ryuki ^a   Ohno, Jun ^a   Iwahashi, Teruaki ^b   Taniguchi, Kunihisa ^a  

^a FUKUOKA DENTAL COLLEGE   (Japan)

^b SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Lymphangioegnesis; Lymphatic metastasis; Oral melanoma; Sentinel lymph node; Tumor bearing lymph node

Indexed keywords

LYMPHATIC VESSEL ENDOTHELIAL HYALURONAN RECEPTOR 1; RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INVASION; CANCER MODEL; CANCER TISSUE; CELL INTERACTION; CERVICAL LYMPH NODE; CONTROLLED STUDY; FEMALE; HISTOLOGY; HISTOPATHOLOGY; IMMUNOFLUORESCENCE MICROSCOPY; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHADENOPATHY; LYMPHANGIOGENESIS; MELANOMA; MELANOMA B16; MELANOMA CELL; MORPHOMETRICS; MOUSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; TUMOR CELL;

ANIMALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; PROGNOSIS; UTERINE CERVICAL NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84866792427     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/1756-9966-31-83     Document Type: Article

References (24)

1. A surgeon looks at cervical lymph nodes. Johnson JT, Radiology 1990 175 607 610 2188292
2. Lymphangiogenesis and tumor metastasis: myth or reality? Pepper MS, Clin Cancer Res 2001 7 462 468 11297234
3. Is there a role for sentinel node biopsy in early N0 tongue tumors? Chiesa F, Mauri S, Grana C, Tradati N, Calabrese L, Ansarin M, Mazzarol G, Paganelli G, Surgery 2000 128 16 21 10.1067/msy.2000.106809 10876180
4. Cancer metastasis as a therapeutic target. Sleeman J, Steeg PS, Eur J Cancer 2010 46 1177 1180 10.1016/j.ejca.2010.02.039 20307970
5. Ioachim HL, Medeiros LJ, Tumor-reactive lymphadenopathy Philadelphia: Lippincott Williams & Wilkins Fourth Edition 2009
6. Tumor and lymph node lymphangiogenesis-impact on cancer metastasis. Tobler NE, Detmar M, J Leukoc Biol 2006 80 691 696 10.1189/jlb.1105653 16793912
7. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. He Y, Kozaki K, Karpanen T, Koshikawa K, Yla-Herttuala S, Takahashi T, Alitalo K, Nat Cancer Inst 2002 94 819 825 10.1093/jnci/94.11.819
8. Tumor lymphangiogenesis and melanoma metastasis. Rinderknecht M, Detmar M, J Cell Physiol 2008 216 347 354 10.1002/jcp.21494 18481261
9. Preparing the soil: the primary tumor induces vasculature reorganization in the sentinel lymph node before the arrival of metastatic cancer cells. Qian CN, Berghuis B, Tsarfaty G, Bruch M, Kort EJ, Ditlev J, Tsarfaty I, Hudson E, Jackson DG, Petillo D, Chen J, Resau JH, The BT, Cancer Res 2006 66 10365 10376 10.1158/0008-5472.CAN-06-2977 17062557
10. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. Hirakawa S, Kodama S, Kunstfeld R, Kajiya K, Brown LF, Detmar M, J Exp Med 2005 201 1089 1099 10.1084/jem.20041896 15809353
11. Tumor-induced sentinel lymph node lymphangiogenesis and increased lymph flow precede melanoma metastasis. Harrell MI, Iritani BM, Ruddell A, Am J Pathol 2007 170 774 786 10.2353/ajpath.2007.060761 17255343
12. VEGF-C-induced lymphangiogenesis in sentinel lymph nodes promotes tumor metastasis to distant sites. Hirakawa S, Brown LF, Kodama S, Paavonen K, Alitalo K, Detmar M, Blood 2007 109 1010 1017 17032920
13. The role of tumor lymphangiogenesis in metastatic spread. Stacker SA, Baldwin ME, Achen MG, FASEB J 2002 16 922 934 10.1096/fj.01-0945rev 12087053
14. Role of lymphangiogenic factors in tumor metastasis. He Y, Karpanen T, Alitalo K, BiochimBiophys Aacta 2004 1654 3 12
15. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. Joukov V, Pajusola K, Kaipainen A, Chilov D, Lahtinen I, Kukk E, Saksela O, Kalkkinen N, Alitalo K, EMBO J 1996 15 290 298 8617204
16. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Achen MG, Jeltsch M, Kukk E, Mäkinen T, Vitali A, Wilks AF, Alitalo K, Stacker SA, Proc Natl Acad Sci USA 1998 95 548 553 10.1073/pnas.95.2.548 9435229
17. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. Mandriota SJ, Jussila L, Jeltsch M, Compagni A, Baetens D, Prevo R, Banerji S, Huarte J, Montesano R, Jackson DG, Orci L, Alitalo K, Christofori G, Pepper MS, EMBO J 2001 20 672 682 10.1093/emboj/20.4.672 11179212
18. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Stacker SA, Caesar C, Baldwin ME, Thornton GE, Williams RA, Prevo R, Jackson DG, Nishikawa S, Kubo H, Achen MG, Nat Med 2001 7 186 191 10.1038/84635 11175849
19. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Skobe M, Hawighorst T, Jackson DG, Prevo R, Janes L, Velasco P, Riccardi L, Alitalo K, Claffey K, Detmar M, Nat Med 2001 7 192 198 10.1038/84643 11175850
20. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. He Y, Rajantie I, Pajusola K, Jeltsch M, Holopainen T, Yla-Herttuala S, Harding T, Jooss K, Takahashi T, Alitalo K, Cancer Res 2005 65 4739 4746 10.1158/0008-5472.CAN-04-4576 15930292
21. Dynamics of lymphatic vessels during nodal metastasis of oral malignant melanoma in mice. Iwahashi T, Ohno J, Okamura K, Ozeki S, Taniguchi K, Oral Med Pathol 2008 12 47 52 10.3353/omp.12.47
22. Limited capability of regional lymph nodes to eradicate metastatic cancer cells. Nagata H, Arai T, Soejima Y, Suzuki H, Ishii H, Hibi T, Cancer Res 2004 64 8239 8248 10.1158/0008-5472.CAN-04-1182 15548690
23. LYVE-1, a new homologue of the CD44 glycoprotein, is a lymph-specific receptor for hyaluronan. Banerji S, Ni J, Wang SX, Clasper S, Su J, Tammi R, Jones M, Jackson DG, J Cell Biol 1999 144 789 801 10.1083/jcb.144.4.789 10037799
24. LYVE-1, the lymphatic system and tumor lymphangiogenesis. Jackson DG, Prevo R, Clasper S, Banerji S, Trends Immunol 2001 22 317 321 10.1016/S1471-4906(01)01936-6 11377291